Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation
JAMA, Vol. 329(18), p. 1607-1608, 2023 doi:10.1001/jama.2023.3079
Posted: 19 Jul 2023 Last revised: 9 Sep 2023
Date Written: May 1, 2023
Abstract
This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.
Keywords: Orphan Drug Act, pharmaceutical investment, statutory incentive, FDA, Orphan Drug Designations and Approvals
JEL Classification: K11, K10, K23
Suggested Citation: Suggested Citation
Tu, Shine (Sean) and Nagar, Sarosh and Kesselheim, Aaron S. and Lu, Zhigang and Rome, Benjamin N., Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation (May 1, 2023). JAMA, Vol. 329(18), p. 1607-1608, 2023 doi:10.1001/jama.2023.3079, WVU College of Law Research Paper, No. 2023-014, Available at SSRN: https://ssrn.com/abstract=4510296
Shine (Sean) Tu (Contact Author)
West Virginia University College of Law ( email )
101 Law School Drive
Morgantown, WV West Virginia 26506
United States
HOME PAGE: http://https://www.law.wvu.edu/faculty-staff/faculty/s-sean-tu
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.